It is becoming clear that many cancer treatments can induce pre-mature senescence and senescence-associated secretory phenotype (SASP), leading to ageing-related diseases and cardiovascular disease (CVD). Telomere dysfunction and telomeric DNA damage caused by cancer treatments can sustain for a longer period of time and triggers persistent DNA damage response (DDR) for months. The interplay between mitochondria and nucleus in promoting persistent DDR and SASP has been suggested. Furthermore, epigenetic changes and endothelial-to-mesenchymal transition may contribute to SASP, but the exact regulatory mechanism remains unclear. Importantly, since SASP can be detrimental to both cancer prognosis and cardiovascular injury, targeting SASP in cancer patients can be an ideal strategy to prevent CVD in cancer survivors.
This Research Topic aims to shed new light not only on acute cardiotoxicity but also on the chronic and long-lasting effects of various cancer treatments on the cardiovascular system. Since the prognosis of cancer patients after cancer treatments significantly improves, the long-lasting effects of cancer treatments on the cardiovascular system will have a significant impact on their overall survival by increasing the incidents of ischemic heart disease, hypertension, arrhythmia, cardiac dysfunction, including heart failure preserved ejection fraction, metabolic disorders including diabetes, hyperlipidemia, and obesity. Since many different factors will be involved in developing long-lasting effects of cancer and cancer treatments after the completion, it is challenging to generate a good strategy and systemic approaches to understanding the long-lasting effects of cancer treatments on cardiovascular systems. We encourage all the scientists and physicians willing to challenge this difficulty and help us establish a new direction and strategy to define how cancer treatments can cause long-lasting effects on cardiovascular systems like a “curse” and allow us to erase this curse from cancer patients.
All types of articles, including review articles, original research articles, case reports, letters to the editors, short communications, perspectives, and clinical trial reports, will be acceptable. However, the case reports and review articles need to show some novel directions and aspects of the approaches, analysis, evaluations, treatments, and mechanisms for each cancer treatment-associated cardiovascular disease.
It is becoming clear that many cancer treatments can induce pre-mature senescence and senescence-associated secretory phenotype (SASP), leading to ageing-related diseases and cardiovascular disease (CVD). Telomere dysfunction and telomeric DNA damage caused by cancer treatments can sustain for a longer period of time and triggers persistent DNA damage response (DDR) for months. The interplay between mitochondria and nucleus in promoting persistent DDR and SASP has been suggested. Furthermore, epigenetic changes and endothelial-to-mesenchymal transition may contribute to SASP, but the exact regulatory mechanism remains unclear. Importantly, since SASP can be detrimental to both cancer prognosis and cardiovascular injury, targeting SASP in cancer patients can be an ideal strategy to prevent CVD in cancer survivors.
This Research Topic aims to shed new light not only on acute cardiotoxicity but also on the chronic and long-lasting effects of various cancer treatments on the cardiovascular system. Since the prognosis of cancer patients after cancer treatments significantly improves, the long-lasting effects of cancer treatments on the cardiovascular system will have a significant impact on their overall survival by increasing the incidents of ischemic heart disease, hypertension, arrhythmia, cardiac dysfunction, including heart failure preserved ejection fraction, metabolic disorders including diabetes, hyperlipidemia, and obesity. Since many different factors will be involved in developing long-lasting effects of cancer and cancer treatments after the completion, it is challenging to generate a good strategy and systemic approaches to understanding the long-lasting effects of cancer treatments on cardiovascular systems. We encourage all the scientists and physicians willing to challenge this difficulty and help us establish a new direction and strategy to define how cancer treatments can cause long-lasting effects on cardiovascular systems like a “curse” and allow us to erase this curse from cancer patients.
All types of articles, including review articles, original research articles, case reports, letters to the editors, short communications, perspectives, and clinical trial reports, will be acceptable. However, the case reports and review articles need to show some novel directions and aspects of the approaches, analysis, evaluations, treatments, and mechanisms for each cancer treatment-associated cardiovascular disease.
